Envista/$NVST
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Envista
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.
- Ticker
- $NVST
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 12,000
- Headquarters
- Brea, United States
- Website
- envistaco.com
Envista Metrics
BasicAdvanced
$4B
6.41
$3.85
0.94
-
Price and volume
Market cap
$4B
Beta
0.94
52-week high
$30.42
52-week low
$18.77
Average daily volume
3.2M
Financial strength
Current ratio
2.452
Quick ratio
1.969
Long term debt to equity
0.502
Total debt to equity
0.514
Interest coverage (TTM)
8.91%
Profitability
EBITDA (TTM)
416.2
Gross margin (TTM)
55.48%
Net profit margin (TTM)
22.01%
Operating margin (TTM)
10.59%
Effective tax rate (TTM)
7.42%
Revenue per employee (TTM)
$240,000
Management effectiveness
Return on assets (TTM)
3.38%
Return on equity (TTM)
20.52%
Valuation
Price to earnings (TTM)
6.409
Price to revenue (TTM)
1.394
Price to book
1.28
Price to tangible book (TTM)
26.02
Price to free cash flow (TTM)
16.584
Free cash flow yield (TTM)
6.03%
Free cash flow per share (TTM)
1.487
Growth
Revenue change (TTM)
9.78%
Earnings per share change (TTM)
4,373.75%
3-year revenue growth (CAGR)
3.69%
3-year earnings per share growth (CAGR)
52.70%
What the Analysts think about Envista
Analyst ratings (Buy, Hold, Sell) for Envista stock.
Analyst projections of the future price of Envista stock.
Bulls say / Bears say
Envista raised its 2026 adjusted EPS outlook to $1.54–$1.58 and EBITDA growth outlook to 12.5%–14%, while narrowing its core sales growth range. That points to improving earnings momentum and management confidence in delivery. (PR Newswire)
The product pipeline is showing signs of traction: Spark aligners grew at a high-single-digit rate in Q3, while diagnostics and implants each grew at mid-single-digit rates. S&P also sees Spark’s share gains and new implant launches as supports for medium-term growth. (The Motley Fool, S&P Global Ratings)
Operational improvements are lifting profitability and leave Envista with financial flexibility: Q3 adjusted EBITDA margin rose 80 basis points, free-cash-flow conversion was 97%, and net debt was 0.6 times adjusted EBITDA. The company also expects roughly 100% free-cash-flow conversion for 2026. (The Motley Fool, PR Newswire)
China’s volume-based procurement creates a significant pricing risk: Envista expects orthodontic prices to fall about 50% and implant prices by 10%–15% when the programme takes effect, likely in the first half of 2027. Distributor destocking already helped drive a low-double-digit decline in China sales in Q3. (The Motley Fool)
Demand remains uneven in the US, where management said macro uncertainty is weighing on patient and clinician confidence; elective orthodontics and implants are still running below their higher historical trends. This leaves Envista exposed to slower demand in important product lines. (The Motley Fool)
Q3 GAAP net income included a $428.1 million foreign-currency translation gain, lifting diluted EPS to $3.11, compared with adjusted EPS of $0.40. The exceptional gain makes headline profit a poor guide to recurring earnings. (StockTitan, PR Newswire)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.
Envista Financial Performance
Revenues and expenses
Envista Earnings Performance
Company profitability
Upcoming events
No upcoming events
Envista News
AllArticlesVideos
Funds containing Envista
Fund name | Fund size | $NVST weighting |
|---|---|---|
SPDR S&P 400 US Mid Cap$SPY4 | $5.9B | 0.12% |
SPDR S&P 400 US Mid Cap£SPX4 | $5.9B | 0.12% |
Xtrackers S&P 500 Swap£XSPX | $9.1B | 0.10% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $2.7B | 0.06% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $2.7B | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.